NCT03080545

Enstilar in Combination With Biologic Agents

An Open-Label, Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Biologic Agents

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Psoriasis Treatment Center of Central New Jersey · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients receiving biologic therapy with 5% or less body surface area will receive Enstilar topical foam for 16 weeks.

Detailed description

A two-phase, single center, observational study of 25 subjects to assess 4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QD on two consecutive days a week to patients with ≤5% BSA who are receiving biologic therapy for at least 24 weeks

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Enstilar 0.005%-0.064% Topical Foam	Topical foam

Timeline

• Start date: 2017-05-01
• Primary completion: 2017-10-30
• Completion: 2017-10-30
• First posted: 2017-03-15
• Last updated: 2018-01-03

Locations

1 site across 1 country: United States